Thomas A, Danon L, Christensen H, Northstone K, Smith D, Nixon E, Trickey A, Hemani G, Sauchelli S, Finn A, Timpson N, Brooks-Pollock E. Limits of lockdown: characterising essential contacts during physical distancing. Wellcome Open Res. 2021 May;6:116. doi: 10.12688/wellcomeopenres.16785.1
Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Shi K, Zhao Y, Miao L, Satterlee A, Haynes M, Luo C, Musetti S, Huang L. Dual functional LipoMET mediates envelope-type nanoparticles to combinational oncogene silencing and tumor growth inhibition. Mol Ther. 2017 Jul 5;25(7):1567-79. doi: 10.1016/j.ymthe.2017.02.008
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.